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Marieke Rienks, MD, PHD, Abhishek Joshi, BA, MBCHB, MD, Manuel Mayr, MD, PHDP atients with diabetes are at risk of vascularcomplications, leading to cardiovascular,renal, and neurological disease. In this issue
of JACC: Basic to Translational Science, Wang et al.
(1) suggest that impaired infarct healing in
diabetics results from a hyperinsulinemia- and
hyperglycemia-induced down-regulation of microri-
bonucleic acid (microRNA, miRNA)-24 (miR-24). The
authors ascribe the protective effect of miR-24 to
repression of protein targets involved in apoptosis,
autophagy, and protein O-GlcNAcylation. Raising
miR-24 is proposed as a potential therapeutic
approach for improving post-infarct healing in pa-
tients with type 2 diabetes (T2D).SEE PAGE 350In contrast with the absence of a preventative
beneﬁt of intense glucose control in a primary pre-
vention setting (2), incident acute myocardial infarc-
tion (MI) in diabetic patients is associated with
increased subsequent heart failure and mortality (3),
both during initial hospitalization and long-term
follow-up. However, early enthusiasm for intensive
insulin treatment has given way to an agnosticISSN 2452-302X
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Science author instructions page.approach, as large studies found beneﬁts and poten-
tial harm associated with these strategies (4). The
higher mortality and complication rates in T2D pa-
tients are multifactorial and probably related to the
duration of glycemic dysregulation. Why do T2D pa-
tients treated with insulin fail to show an improved
clinical outcome?
Wang et al. (1) suggest that insulin therapy, added
to higher baseline insulin levels reduces miR-24
levels, with adverse effects after ischemic injury.
According to the authors, this may, at least in part,
explain the lack of therapeutic efﬁcacy of insulin
treatment in T2D patients post-MI.
A strength of this study is the use of 2 murine
models, one akin to T2D and type 1 diabetes (T1D).
Although insulin use increased mortality post-MI in
db/db mice (T2D), insulin use decreased mortality in
mice treated with streptozotocin (T1D). Wang et al.
demonstrate a reduction in infarct size after
ischemia reperfusion in db/db mice after systemic
administration of nanoparticles containing miR-24
as well as in transgenic mice that have
cardiomyocyte-speciﬁc overexpression of miR-24.
O-GlcNAc transferase, Bcl-2-like protein 11, and
autophagy-related 4A cysteine peptidase are the
proposed targets of miR-24 responsible (Figure 1).
Similar to most miRNAs, miR-24 is ubiquitously
expressed (5). Qian et al. (6) have previously shown
that in vivo administration of miR-24 nanoparticles
inhibited cardiomyocyte apoptosis in a mouse
model of MI, thereby attenuating infarct size and
reducing cardiac dysfunction by directly acting on
Bcl-2-like protein 11.
MiR-24 is also part of a pri-miR cluster, together
with miR-23 and miR-27 (7). Increased expression
of miR-24 but also of miR-27b has been associated
with cardiac dysfunction (8,9). Previously, the au-
thors reported that hyperglycemia represses miR-24
in endothelial cells. Reduced miR-24 was associ-
ated with increased von Willebrand factor secretion
by endothelial cells (10). Notably, Fiedler et al. (11)https://doi.org/10.1016/j.jacbts.2018.05.002
FIGURE 1 MiR-24 and the Diabetic Heart
The infarct size after ischemia-reperfusion is reduced in a mouse model of type 2 diabetes upon microribonucleic acid 24 (miR-24) overexpression. O-GlcNAc transferase
(OGT), Bcl-2-like protein 11 (BIM), and autophagy-related 4A cysteine peptidase (ATG4A) are proposed as targets of miR-24. Insulin treatment reduced mortality in a
mouse model of type 1 diabetes, but not type 2 diabetes. The observed plasma changes in miR-24 may not be connected to myocardial tissue.
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364revealed that miR-24 is up-regulated after MI and
enriched in cardiac endothelial cells under normo-
glycemia. Blocking endothelial miR-24 using anta-
gomirs limited infarct size by preventing
endothelial cell apoptosis and enhancing vascu-
larity (6). Thus, miR-24 appears to affect both
endothelial cells and cardiomyocytes, with opposite
outcomes in post-MI remodeling
Wang et al. further demonstrate a decrease in
miR-24 in response to hyperinsulinemia in a clamp
study in 5 T1D patients. A signiﬁcant decrease in
miR-24 levels was observed in the plasma of T2D
compared with T1D patients. We have recently
identiﬁed miR-24 as an abundant miRNA in plate-
lets. Its plasma levels are reduced by antiplatelet
therapy (12). Diabetics are known to have increased
platelet reactivity (13). Reduced platelet miRNAs,
including miR-24, were among the predominant
changes in circulating miRNAs in patients with T2D
(14,15). Insulin antagonizes platelet activation, but
platelets from T2D are less sensitive to this effect
due to their insulin resistance (15). Therefore, dif-
ferential miR-24 detection in the plasma of T2D
may reﬂect differential platelet reactivity,especially as the plasma isolation protocol in Wang
et al. does not prevent pre-analytic platelet acti-
vation (16). The rapid reduction of plasma miR-24
seen in Wang et al.’s glucose clamp experiment
supports this suggestion; as insulin levels increase,
platelet reactivity is reduced and platelet “poor”
plasma subsequently demonstrates reduced miR-24
levels (17).
Although it would be an oversimpliﬁcation to
attribute myocardial dysfunction after MI in T2D to
the dysregulation of an individual miRNA such as
miR-24, the study by Wang et al. emphasizes the
signiﬁcance of miR-24 in the ischemic diabetic heart
(Figure 1). Also, the proposed role for circulating
miRNAs such as miR-24 in the pathophysiology of
infarct healing in diabetics in relation to insulin
sensitivity and production as demonstrated by this
study encourages further exploration.
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